Characteristics of the study population
| Characteristic . | N = 592 . |
|---|---|
| Median, age, y (range) | 54 (8-74) |
| Sex, n (%) | |
| Male | 356 (60.1) |
| Female | 236 (39.9) |
| Race, n (%) | |
| White | 512 (86.5) |
| Other | 43 (13.5) |
| Diagnosis, n (%) | |
| AML/MDS | 255 (43.1) |
| Lymphoma/CLL | 212 (35.8) |
| CML/MPD | 54 (9.1) |
| ALL | 42 (7.1) |
| Other | 29 (4.9) |
| Preparative regimen, n (%) | |
| Myeloablative | 351 (59.3) |
| Reduced-intensity/nonmyeloablative | 241 (40.7) |
| Source of stem cells, n (%) | |
| Peripheral blood | 358 (60.5) |
| BM | 234 (39.5) |
| CD34+ cells infused, median, n (range)* | 4.6 (0.8-36.4) |
| HLA-DPB1 mismatch, n (%) | 430 (72.6%) |
| HLA match (HVG direction), n (%) | |
| 10/10 | 495 (83.6%) |
| 0-DP mismatch | 140 |
| 1-DP mismatch | 257 |
| 2-DP mismatch | 98 |
| 9/10 | 97 (16.4%) |
| 0-DP mismatch | 21 |
| 1-DP mismatch | 52 |
| 2-DP mismatch | 24 |
| Distribution of LEL mismatches in 8/8 and 7/8 transplants, n (%) | 8/8 HVG (n = 520) 7/8 HVG (n = 72) |
| 0 DPB1 HVG mismatch | 136 (26.2%) 18 (25%) |
| 1 DPB1 HVG mismatch | 280 (53.8%) 38 (52.8%) |
| 2 DPB1 HVG mismatch | 104 (20.0%) 16 (22.2%) |
| DQB1 HVG mismatch | 29 (5.6%) 1 (1.4%) |
| DRB3 HVG mismatch | 24 (4.6%) 4 (5.6%) |
| DRB4 HVG mismatch | 5 (1.0%) 0 (0.0%) |
| DRB5 HVG mismatch | 0 (0.0%) 0 (0.0%) |
| Sex mismatch between the donor and recipient, n (%)† | |
| No | 416 (70.9) |
| Yes | 170 (29.1) |
| CMV mismatch between the donor and recipient, n (%)† | |
| No | 312 (53.9) |
| Yes | 267 (46.1) |
| ABO mismatch between the donor and recipient, n (%)† | |
| No | 243 (41.1) |
| Yes | 348 (58.9) |
| Pregnancies, median, n (range) | 2 (0-7) |
| Engrafted, n (%) | 573 (96.8) |
| Time to ANC 500, median, d | 12 |
| Time to PLT 20 000, median, d | 14 |
| Relapsed, n (%) | |
| No | 421 (71.1) |
| Yes | 171 (28.9) |
| Alive at the last follow-up, n (%) | |
| Yes | 274 (46.3) |
| No | 318 (53.7) |
| Characteristic . | N = 592 . |
|---|---|
| Median, age, y (range) | 54 (8-74) |
| Sex, n (%) | |
| Male | 356 (60.1) |
| Female | 236 (39.9) |
| Race, n (%) | |
| White | 512 (86.5) |
| Other | 43 (13.5) |
| Diagnosis, n (%) | |
| AML/MDS | 255 (43.1) |
| Lymphoma/CLL | 212 (35.8) |
| CML/MPD | 54 (9.1) |
| ALL | 42 (7.1) |
| Other | 29 (4.9) |
| Preparative regimen, n (%) | |
| Myeloablative | 351 (59.3) |
| Reduced-intensity/nonmyeloablative | 241 (40.7) |
| Source of stem cells, n (%) | |
| Peripheral blood | 358 (60.5) |
| BM | 234 (39.5) |
| CD34+ cells infused, median, n (range)* | 4.6 (0.8-36.4) |
| HLA-DPB1 mismatch, n (%) | 430 (72.6%) |
| HLA match (HVG direction), n (%) | |
| 10/10 | 495 (83.6%) |
| 0-DP mismatch | 140 |
| 1-DP mismatch | 257 |
| 2-DP mismatch | 98 |
| 9/10 | 97 (16.4%) |
| 0-DP mismatch | 21 |
| 1-DP mismatch | 52 |
| 2-DP mismatch | 24 |
| Distribution of LEL mismatches in 8/8 and 7/8 transplants, n (%) | 8/8 HVG (n = 520) 7/8 HVG (n = 72) |
| 0 DPB1 HVG mismatch | 136 (26.2%) 18 (25%) |
| 1 DPB1 HVG mismatch | 280 (53.8%) 38 (52.8%) |
| 2 DPB1 HVG mismatch | 104 (20.0%) 16 (22.2%) |
| DQB1 HVG mismatch | 29 (5.6%) 1 (1.4%) |
| DRB3 HVG mismatch | 24 (4.6%) 4 (5.6%) |
| DRB4 HVG mismatch | 5 (1.0%) 0 (0.0%) |
| DRB5 HVG mismatch | 0 (0.0%) 0 (0.0%) |
| Sex mismatch between the donor and recipient, n (%)† | |
| No | 416 (70.9) |
| Yes | 170 (29.1) |
| CMV mismatch between the donor and recipient, n (%)† | |
| No | 312 (53.9) |
| Yes | 267 (46.1) |
| ABO mismatch between the donor and recipient, n (%)† | |
| No | 243 (41.1) |
| Yes | 348 (58.9) |
| Pregnancies, median, n (range) | 2 (0-7) |
| Engrafted, n (%) | 573 (96.8) |
| Time to ANC 500, median, d | 12 |
| Time to PLT 20 000, median, d | 14 |
| Relapsed, n (%) | |
| No | 421 (71.1) |
| Yes | 171 (28.9) |
| Alive at the last follow-up, n (%) | |
| Yes | 274 (46.3) |
| No | 318 (53.7) |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndromes; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MPD, myeloproliferative diseases; ALL, acute lymphoblastic leukemia; PRBCs, packed red blood cells; and PLT, platelet count.
Data were available for 590 patients.
Donor sex known for 586 patients, donor CMV known for 579 patients, and donor ABO known for 591 patients.